Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion

Two new targeted agents have been approved for pediatric and adult patients with advanced or metastatic solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation. Larotrectinib and entrectinib are the second and third agents to be approved as...

Descripción completa

Detalles Bibliográficos
Autor principal: Dunn, Danielle B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Prescriberߣs Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863124/
https://www.ncbi.nlm.nih.gov/pubmed/33604102
http://dx.doi.org/10.6004/jadpro.2020.11.4.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863124/
https://www.ncbi.nlm.nih.gov/pubmed/33604102
http://dx.doi.org/10.6004/jadpro.2020.11.4.9

Ejemplares similares